JPMorgan upgrades Sanofi stock rating to Overweight on favorable pipeline outlook

JPMorgan has upgraded Sanofi (SNY) to Overweight from Neutral, adjusting its price target to EUR105.00, citing a more favorable catalyst path for key pipeline assets like Amlitemab and tolebrutinib, each projected to exceed EUR1 billion in sales. Despite shares being weighed by mixed H1 2025 readouts, the firm highlights Sanofi's attractive valuation at a 20% discount to the sector and 9x 2026 earnings, coupled with robust 5% sales and 7% EPS CAGRs through 2030, making current price levels a compelling entry point even if pipeline assets are conservatively valued at zero.

Analysis

JPMorgan has upgraded Sanofi (SNY) to Overweight from Neutral, signaling a bullish turn despite lowering its price target to EUR105.00 from EUR110.00. The upgrade is predicated on a more favorable catalyst path for Sanofi's drug pipeline over the next 6-12 months, which follows a period where mixed trial readouts weighed on the stock. The bank specifically highlights high-potential assets Amlitemab and tolebrutinib, projecting each could generate over EUR 1 billion in sales and expressing confidence in their respective trials meeting primary endpoints. The core of the investment thesis rests on valuation; Sanofi is currently trading at a significant 20% discount to the sector on a 9x 2026 earnings multiple. This discounted valuation is juxtaposed with a robust growth outlook, including a projected 7% EPS CAGR from 2025-2030, which is 50% above the sector average. JPMorgan's analysis concludes that the company's ex-pipeline Embedded Value alone is EUR105, suggesting the market is currently assigning zero value to the entire pipeline and making the present share price a compelling entry point.

Key Decisions for Investors

• Investors should consider the upgrade a key signal that the narrative around Sanofi may shift from its recent pipeline setbacks to its future high-potential catalysts within the next 6-12 months.
• The current valuation presents a value-oriented opportunity, as JPMorgan's analysis suggests the stock is priced at its core value, effectively offering the potential upside from its multi-billion dollar pipeline at no additional cost.
• Portfolio managers could view Sanofi as a compelling Growth at a Reasonable Price (GARP) candidate, given its combination of a 20% sector valuation discount and a projected EPS growth rate 50% above its peers.
• Key risk to monitor will be the clinical trial results for Amlitemab and tolebrutinib; a failure to meet primary endpoints would materially undermine the core of this bullish thesis.